The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
about
JAMM: a metalloprotease-like zinc site in the proteasome and signalosomeHigh-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical librariesHuman desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by ToremifeneInvolvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosisMatrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitorsAntidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chainContributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction.Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.Zinc-binding groups modulate selective inhibition of MMPs.Chemical proteomics: terra incognita for novel drug target profiling.Nitroglycerin alters matrix remodeling proteins in THP-1 human macrophages and plasma metalloproteinase activity in rats.Identification of protein fold topology shared between different folds inhibited by natural products.A glimpse of matrix metalloproteinases in diabetic nephropathy.Extracellular proteases as targets for drug developmentInhibition of hippocampal matrix metalloproteinase-3 and -9 disrupts spatial memory.The role of ECM molecules in activity-dependent synaptic development and plasticity.Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.Small molecular anti-cytokine agents.Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.Matrix metalloproteinase 11 (MMP-11; stromelysin-3) and synthetic inhibitors.Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Structure-based organic synthesis of drug prototypes: a personal odyssey.Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.Matrix metalloproteinases: drug targets for myocardial infarction.Inhibition of matrix metalloproteinase-2 by PARP inhibitors.Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders.The GRID/CPCA approach in drug discovery.Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium.A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation.Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12.Molecular Descriptors in Modelling the Tumour Necrosis Factor-α Converting Enzyme Inhibition Activity of Novel Tartrate-Based Analogues.Resonance assignments for stromelysin complexed with a beta-sulfonyl hydroxamate inhibitor.Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity.The role of matrix metalloproteinases -9 and -2 in development of neonatal chronic lung disease.Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachmentExpression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment
P2860
Q21092836-F604C636-366A-4C6E-8A2F-51BF1F063E04Q24656146-3E43E1D9-0135-41CB-BDC7-B61B8718080BQ24803335-23E15432-E101-4283-9BD0-F296330D2F70Q26744390-349C093F-0D25-42F8-BEE1-65443B6BE682Q27647435-015F3616-5D11-426F-AACB-9DA2F489DE84Q27677320-71C851C6-4E48-4279-9BB1-EE40DE98724DQ30483239-91F6F2E6-D690-4466-BE92-B6DE38A38010Q33613286-60987BD4-1CDD-49AF-BE0E-7C155A6BD1DDQ33718245-7881834F-5ED6-4A50-9F98-1CF97B8235E7Q34284580-9E551EAA-926F-40AE-9E62-C581D6A8D0F9Q34574503-CF7D857D-0E5B-491F-B9E9-F221C9DC1498Q34618490-A656257E-B177-4761-99AD-95C9F7EA51BFQ34796034-B8DA1739-F987-40AF-BD7F-76B13AE00B55Q35116202-7A6E16CA-6D66-4744-9A33-DCB05FE4AF97Q35723480-4269978C-A0FB-4121-AF8E-3D85DF8E2D51Q35726733-D59BC79F-ED85-4EC2-A1FF-5FDAAC197473Q36009930-CE909460-5E8B-42C2-BE7A-34BD5198EA29Q36311663-B511BBAF-C0A8-4986-8357-29153C50C523Q36316444-D3AACEBE-CE74-42BB-A40E-14B9FFC97396Q36482629-2341FF64-3EA4-40CE-BC99-97EF94AB44E1Q36644577-CD7CF5D1-C7F0-482A-A4EB-DDC07AA28B76Q36647895-3ED6BD28-61E6-49FD-9BD7-BF3AB2161552Q36995248-5F84DAF6-6DC5-4817-A64C-D87520451E2EQ37308645-8758BC19-FD30-408B-B65E-2BEA1C6ED940Q37373723-95CFD506-97FA-4323-9D0E-64E7AF2ADB3AQ37757028-98FFBA04-AA28-4630-9298-6D2696A97F02Q38028540-CA3FC588-54D2-42B1-B78E-8CE44777365FQ38076737-AE50C296-6080-41E2-90EC-51E069E3EFDEQ39061829-115DEA9F-3F99-40D5-8DA3-F7A270DE3E4DQ39573243-04595AB2-ECEC-4178-8C0B-C8AD949E4ED3Q42064935-7AE59F98-39A5-4830-9157-C4E073A54A6BQ43248813-4EE618CE-4843-4111-A250-800689EA7218Q46497632-0FF0EA05-0DB2-4BBE-BF5E-BC456F2C0D73Q47222545-EDF4427D-9277-4DD1-A95A-89E28A5EAB2CQ47223491-0BB7F575-CEF8-4FA3-8772-A31A4EB3212AQ50916304-E7DDDDAE-679B-4F94-B433-E45DCD23B207Q51055817-DE27CC44-F5C5-4335-91D4-7E6B88410661Q51830769-5FE9D44D-627D-4257-8B2D-BBE140772DE6Q58217628-447BA3D5-16D9-49F6-8733-B7A70D50FDBBQ58217653-23BAFFD1-5FFA-425F-B0B0-F4CB0F06121B
P2860
The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
The design, structure, and the ...... metalloproteinase inhibitors.
@ast
The design, structure, and the ...... metalloproteinase inhibitors.
@en
The design, structure, and the ...... metalloproteinase inhibitors.
@nl
type
label
The design, structure, and the ...... metalloproteinase inhibitors.
@ast
The design, structure, and the ...... metalloproteinase inhibitors.
@en
The design, structure, and the ...... metalloproteinase inhibitors.
@nl
prefLabel
The design, structure, and the ...... metalloproteinase inhibitors.
@ast
The design, structure, and the ...... metalloproteinase inhibitors.
@en
The design, structure, and the ...... metalloproteinase inhibitors.
@nl
P2093
P356
P1476
The design, structure, and the ...... metalloproteinase inhibitors.
@en
P2093
P304
P356
10.2174/0929867013373417
P577
2001-03-01T00:00:00Z